Information Library

White Papers - High-quality studies

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • Managing Pharmacovigilance as a Business

    July 28, 2010
    The three steps required to develop a strategic approach to global capacity management.

  • Regulations for Clinical Studies in Pediatric Patients in the European Union

    March 10, 2010
    After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric

  • New FDA Guidance on Antidiabetic Therapies

    December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • Reinventing the Clinical Trial

    March 31, 2009
    As a new era of drug discovery unfolds, reinventing the clinical trial is essential to medical advancement.

  • Advancing Drug Development Through Pharmacogenomics

    March 31, 2009
    Pharmacogenomics (PG x) is the study of how such genetic differences influence drug therapy. The goal is to use a person’s DNA profile to predict how the individual will respond to a medicine. The ability to predict drug response holds enormous promise to advance the drug development process and to improve drug safety and effectiveness in medical practice.

  • White Paper: EDC Past, Present and Future

    March 25, 2009
    Quintiles has run EDC at more than 19,000 trial sites worldwide, covering more than 310,000 subjects.

  • Monitoring for Quality

    May 22, 2008
    Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.

Page 1 of 1 (7 results)

Subscribe to Email Based on Your Interests

Set preferences